Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avandia rosiglitazone regulatory update

A joint meeting of FDA's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees voted to loosen the REMS for diabetes drug Avandia rosiglitazone from GlaxoSmithKline. Among the 26 members on the panel, 13 voted to modify the REMS, 7 voted to remove the REMS, 5 voted

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers